ARTICLE | Company News
Histogen gene/cell therapy, musculoskeletal news
March 18, 2013 7:00 AM UTC
Histogen and a group of medical device experts formed a JV, PUR Biologics LLC, to develop and commercialize next-generation orthopedic biologics for bone and tissue regeneration. PUR acquired exclusive, worldwide rights to Histogen's human multipotent cell conditioned media (CCM) and extracellular matrix (ECM) materials for use in the orthopedic areas of bone, cartilage, spinal disc and ligament regeneration, as well as device coatings. Histogen declined to disclose details on financial commitments or ownership. ...